SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    HIV sequence database. New Mexico: Los Alamos National Laboratory; Available from: http://www.hiv.lanl.gov
  • 2
    McCutchan FE. Global epidemiology of HIV. J Med Virol 2006;78(Suppl 1):S7-S12.
  • 3
    Lot F, Semaille C, Cazein F, Barin F, Pinget R, Pillonel J, Desenclos JC. Preliminary results from the new HIV surveillance system in France. Eurosurveillance 2004;9:34-7.
  • 4
    Wensing AM, Van De Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, De Mendoza C, Meyer L, Nielsen C, De Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005;192:958-66.
  • 5
    Parry JV, Murphy G, Barlow KL, Lewis K, Rogers PA, Belda FJ, Nicoll A, McGarrigle C, Cliffe S, Mortimer PP, Clewley JP. National surveillance of HIV-1 subtypes for England and Wales: design, methods, and initial findings. J Acquir Immune Defic Syndr 2001;26:381-8.
  • 6
    De Oliveira CF, Diaz RS, Machado DM, Sullivan MT, Finlayson T, Gwinn M, Lackritz EM, Williams AE, Kessler D, Operskalski EA, Mosley JW, Busch MP. Surveillance of HIV-1 genetic subtypes and diversity in the US blood supply. Transfusion 2000;40:1399-406.
  • 7
    Weidle PJ, Ganea CE, Irwin KL, Pieniazek D, McGowan JP, Olivo N, Ramos A, Schable C, Lal RB, Holmberg SD, Ernst JA. Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: a sentinel site for monitoring HIV genetic diversity in the United States. J Infect Dis2000;181:470-5.
  • 8
    Gonzales MJ, Machekano RN, Shafer RW. Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis 2001;184:998-1006.
  • 9
    Brodine SK, Starkey MJ, Shaffer RA, Ito SI, Tasker SA, Barile AJ, Tamminga CL, Stephan KT, Aronson NE, Fraser SL, Wallace MR, Wegner SA, Mascola JR, McCutchan FE. Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS 2003;17:2521-7.
  • 10
    Delwart EL, Orton S, Parekh B, Dobbs T, Clark K, Busch MP. Two percent of HIV-positive U.S. blood donors are infected with non-subtype B strains. AIDS Res Hum Retrovir 2003;19:1065-70.
  • 11
    Hanna GJ, Balaguera HU, Freedberg KA, Werner BG, Steger Craven KA, Craven DE, D'Aquila RT. Drug-selected resistance mutations and non-B subtypes in antiviral-naive adults with established human immunodeficiency virus infection. J Infect Dis 2003;188:986-91.
  • 12
    Achkar JM, Burda ST, Konings FA, Urbanski MM, Williams CA, Seifen D, Kahirimbanyi MN, Vogler M, Parta M, Lupatkin HC, Zolla-Pazner S, Nyambi PN. Infection with HIV type 1 group M non-B subtypes in individuals living in New York City. J Acquir Immune Defic Syndr 2004;36:835-44.
  • 13
    Sides TL, Akinsete O, Henry K, Wotton JT, Carr PW, Bartkus J. HIV-1 subtype diversity in Minnesota. J Infect Dis 2005;192:37-45.
  • 14
    Cartwright CP. The changing epidemiology of HIV/AIDS at a Minnesota hospital: impact of demographic change and viral diversity. J Med Virol 2006;78 Suppl 1:S19-S21.
  • 15
    Lin H-H, Gaschen BK, Collie M, El-Fishaway M, Chen Z, Korber BT, Beatrice ST, Zhang L. Genetic characterization of diverse HIV-1 strains in an immigrant population living in New York City. J Acquir Immune Defic Syndr 2006;41:399-404.
  • 16
    Wheeler W, Mahle K, Bodnar U, Kline R, Hall I, McKenna M, and the US Variant, Atypical and Resistant HIV Surveillance (VARHS) Group. Antiretroviral drug-resistance mutations and subtypes in drug-naive persons newly diagnosed with HIV-1 infection, US March 2003 to October 2006. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Poster 648.
  • 17
    Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-8.
  • 18
    Little SJ, Holte S, Routy J-P, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-94.
  • 19
    Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, Jean-Pierre P, Hogan C, Simon V, Boden D, Markowitz M. Tracking the prevalence of transmitted antiretroviral drug resistant HIV-1. J Acquir Immune Defic Syndr 2006;41:439-46.
  • 20
    Truong H-H, Grant RM, McFarland W, Kellogg T, Kent C, Louie B, Wong E, Klausner JD. Routine surveillance for the detection of acute and recent HIV-infections and transmission of antiretroviral resistance. AIDS 2006;20:2193-7.
  • 21
    Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP; National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid amplification testing. N Engl J Med 2004;351:760-8.
  • 22
    Swanson P, Devare SG, Hackett J Jr. Molecular characterization of 39 HIV-1 isolates representing group M (subtypes A-G) and group O: sequence analysis of gag p24, pol integrase, and env gp41. AIDS Res Hum Retrovir 2003;19:625-9.
  • 23
    Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary infection. AIDS 2003;17:1871-9.
  • 24
    Dodd RY, Notari EP IV, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-9.
  • 25
    Zou S, Notari EP IV, Stramer SL, Wahab F, Musavi F, Dodd RY. Patterns of age- and sex-specific prevalence of major blood-borne infections in United States blood donors, 1995 to 2002: American Red Cross blood donor study. Transfusion 2004;44:1640-7.
  • 26
    Recommendations for deferral of donors for malaria risk. Rockville (MD): US Department of Health and Human Services; July 26, 1994. Available from: http://www.fda.gov/cber/memo.htm
  • 27
    Interim recommendations for deferral of donors at increased risk for HIV-1 group O infection. December 11, 1996. Available from: http://www.fda.gov/cber/bldmem/mem121196a.txt
  • 28
    Pillonel J, Barin F, Laperche S, Bernillon P, Le Vu S, Brunet S, Thierry D, Desenclos JC; Transfusion-Transmissible Agents Working Group of the French Society of Blood Transfusion. Human immunodeficiency virus type 1 incidence among blood donors in France, 1992 through 2006: use of an immunoassay to identify recent infections. Transfusion 2008;48:1567-75.
  • 29
    Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, Parkin N, Boden D, Markowitz M. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002;16:1511-9.
  • 30
    Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM Jr, LaLota M, Dickinson G, Schwarcz S, Torian L, Wendell D, Paul S, Goza GA, Ruiz J, Boyett B, Kaplan JE. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004;189:2174-80.
  • 31
    Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jørgensen LB, Pedersen C, Van Der Hoek L, Prins M, Balotta C, Longo B, Kücherer C, Poggensee G, Ortiz M, De Mendoza C, Gill J, Fleury H, Porter K; CASCADE Collaboration. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 2005;40:505-11.
  • 32
    Schable C, Zekeng L, Pau CP, Hu D, Kaptue L, Gurtler L, Dondero T, Tsague JM, Schochetman G, Jaffe H, George JR. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections. Lancet 1994;343:1393-4.
  • 33
    Ly TD, Laperche S, Brennan C, Vallari A, Ebel A, Hunt J, Martin L, Daghfal D, Schochetman G, Devare S. Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J Virol Methods 2004;122:185-94.
  • 34
    Swanson P, De Mendoza C, Joshi J, Golden A, Hodinka RL, Soriano V, Devare SG, Hackett J Jr. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx® HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR version 1.5, Quantiplex HIV RNA version 3.0, and NucliSens HIV-1 QT. J Clin Microbiol 2005;43:3860-8.